SEAGEN INC (SGEN)

US81181C1045 - Common Stock

228.74  -0.16 (-0.07%)

After market: 228.95 +0.21 (+0.09%)

Fundamental Rating

4

SGEN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SGEN as it has an excellent financial health rating, but there are worries on the profitability. SGEN shows excellent growth, but is valued quite expensive already.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

SGEN had negative earnings in the past year.
SGEN had a negative operating cash flow in the past year.
In the past 5 years SGEN reported 4 times negative net income.
In the past 5 years SGEN reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -20.64%, SGEN belongs to the top of the industry, outperforming 82.06% of the companies in the same industry.
The Return On Equity of SGEN (-29.41%) is better than 81.40% of its industry peers.
Industry RankSector Rank
ROA -20.64%
ROE -29.41%
ROIC N/A
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 75.39%, SGEN belongs to the best of the industry, outperforming 84.88% of the companies in the same industry.
SGEN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%

More info and screens

7

2. Health

2.1 Basic Checks

SGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SGEN has been increased compared to 1 year ago.
Compared to 5 years ago, SGEN has more shares outstanding
There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

SGEN has an Altman-Z score of 23.31. This indicates that SGEN is financially healthy and has little risk of bankruptcy at the moment.
SGEN has a Altman-Z score of 23.31. This is amongst the best in the industry. SGEN outperforms 94.68% of its industry peers.
There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.31
ROIC/WACCN/A
WACC10.94%

2.3 Liquidity

SGEN has a Current Ratio of 2.67. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
SGEN's Current ratio of 2.67 is on the low side compared to the rest of the industry. SGEN is outperformed by 73.26% of its industry peers.
A Quick Ratio of 2.12 indicates that SGEN has no problem at all paying its short term obligations.
The Quick ratio of SGEN (2.12) is worse than 76.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.12

More info and screens

7

3. Growth

3.1 Past

SGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.23%.
The Revenue has grown by 23.40% in the past year. This is a very strong growth!
The Revenue has been growing by 32.40% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%

3.2 Future

Based on estimates for the next years, SGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 32.31% on average per year.
Based on estimates for the next years, SGEN will show a very strong growth in Revenue. The Revenue will grow by 26.49% on average per year.
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SGEN's earnings are expected to grow with 29.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y29.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEAGEN INC

NASDAQ:SGEN (12/13/2023, 8:12:24 PM)

After market: 228.95 +0.21 (+0.09%)

228.74

-0.16 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-01 2023-11-01/bmo
Earnings (Next)02-13 2024-02-13/amc
Inst Owners0.21%
Inst Owner Change0%
Ins Owners0.86%
Ins Owner Change0%
Market Cap43.15B
Analysts72.17
Price Target233.48 (2.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.9%
Min EPS beat(2)-42.41%
Max EPS beat(2)-37.4%
EPS beat(4)1
Avg EPS beat(4)-16.67%
Min EPS beat(4)-42.41%
Max EPS beat(4)24.39%
EPS beat(8)3
Avg EPS beat(8)-5.14%
EPS beat(12)5
Avg EPS beat(12)-16.24%
EPS beat(16)8
Avg EPS beat(16)36.61%
Revenue beat(2)2
Avg Revenue beat(2)2.94%
Min Revenue beat(2)0.14%
Max Revenue beat(2)5.73%
Revenue beat(4)3
Avg Revenue beat(4)3.09%
Min Revenue beat(4)-1.45%
Max Revenue beat(4)7.95%
Revenue beat(8)7
Avg Revenue beat(8)5.12%
Revenue beat(12)10
Avg Revenue beat(12)4.52%
Revenue beat(16)14
Avg Revenue beat(16)12.68%
PT rev (1m)0%
PT rev (3m)1.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-47.4%
EPS NY rev (1m)-17.92%
EPS NY rev (3m)-19.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)101391%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)0.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.76
P/FCF N/A
P/OCF N/A
P/B 16.92
P/tB 20.99
EV/EBITDA N/A
EPS(TTM)-4.01
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-3.72
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS12.19
BVpS13.52
TBVpS10.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.64%
ROE -29.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.39%
FCFM N/A
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
F-Score3
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 219.65%
Cap/Sales 7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2.12
Altman-Z 23.31
F-Score3
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)115.85%
Cap/Depr(5y)145.31%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
EBIT growth 1Y-18.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.02%
EBIT Next 3Y33.65%
EBIT Next 5Y31.94%
FCF growth 1Y-758.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1946.21%
OCF growth 3YN/A
OCF growth 5YN/A